AI in bioanalytical.
AI in bioanalytical work should be treated as controlled workflow support, not autonomous scientific authorship. The evidence question is simple: when a model touches peaks, curves, sample selection, anomaly review, or documentation, can the team still show human accountability, version control, validation logic, and audit trail?
AI in bioanalytical.
Where AI is changing the validation surface · 2026AI in bioanalytical work should be treated as controlled workflow support, not autonomous scientific authorship. iFeed uses PCCP-like thinking as a helpful change-control analogy, but does not present PCCP as a direct bioanalytical regulatory requirement unless a specific source says so.
Peak detection & integration.
AI-assisted peak handling can reduce variability only if the method defines who reviews the boundary, what version of the algorithm was used, how exceptions are handled, and how the audit trail preserves manual overrides.
Calibration-curve fit selection.
Model-assisted fit selection should not hide scientific judgement. The controlled record needs candidate models, weighting rationale, acceptance criteria, reviewer decision, and traceability from run data to reported concentration.
ISR sample selection.
AI can help propose ISR samples across concentration range, time points, and subject factors. Public-facing claims should stop at decision support unless a validated workflow and human approval record are documented.
Anomaly detection.
Assay drift, outlier patterns, missing metadata, and atypical run behaviour are natural AI-support areas. The governance need is model-version control, alert threshold rationale, and documented human disposition.
RCA assistance.
AI may help organise failed-run or failed-ISR evidence, but it should not become the root-cause decision-maker. Human QA/scientific ownership remains the public-safe framing.
PBPK / MIDD.
Model-informed drug development can support regulatory reasoning when assumptions, data sources, model qualification, and limits of use are explicit. It should be described as supportive evidence unless the specific regulatory pathway says otherwise.
Liquid-handling and preparation.
Robotics and automated sample preparation are established operational tools. The bioanalytical risk is not the robot itself; it is method transfer, change control, calibration, maintenance, and exception handling.
Generative authoring.
Generative AI can support drafting or summarisation only when human authorship, source traceability, review responsibility, and data confidentiality are controlled. Validation reports should not imply AI-authored scientific conclusions without accountable human review.
Boundary: This page is an iFeed governance lens. It does not claim that regulators have approved a generic AI/ML pathway for bioanalytical method validation. It maps practical control questions teams should ask before AI touches regulated bioanalytical evidence.
Source anchors: ICH M10 · FDA PCCP guidance for AI-enabled device software functions · FDA AI in Software as a Medical Device. PCCP is used here as a change-control analogy unless the workflow is itself device software subject to that guidance.
Source register.
official anchors · interpretation kept separateThis bioanalytical page uses official guidance as the source layer and separates iFeed interpretation from regulator text. Jurisdiction-specific details should be checked against the current regulator page before use in submissions, audits, or public checklists.
ICH M10 EU page.
EMA ICH M10 scientific guideline. Earlier EMA BMV guidance should be marked as historical where used for comparison.